Core Viewpoint - NorthStrive Fund II LP, owning approximately 5.05% of enVVeno Medical Corporation, is advocating for a change in the company's strategic direction, including a call for a Special Meeting of Shareholders to discuss alternatives to the current plan [1][3][14]. Financial Position - As of September 30, 2025, enVVeno reported approximately $28 million in cash and short-term investments, with no long-term debt, and an annualized cash burn rate of about $16 million, indicating a cash runway of approximately 20-21 months [4]. - The company’s balance sheet is viewed as its primary asset, with an estimated $28.5 million potentially available for distribution after satisfying liabilities in a liquidation scenario [9]. Strategic Recommendations - NorthStrive Fund II suggests halting non-essential clinical expenditures to preserve capital and pursuing either an orderly liquidation or a strategic merger/reverse merger to maximize shareholder value [5][12][16]. - The estimated proceeds from a full liquidation scenario could be approximately $43.47 per share, representing around 335% upside for shareholders, which does not rely on future clinical success or external financing [10][11]. Board Engagement - NorthStrive Fund II has expressed disagreement with the Board's decision not to pursue their recommendations and is formally requesting the Board to call a Special Meeting of Shareholders to allow for a vote on the company's strategic direction [2][3][14]. - The Board collectively owns approximately 10,097 shares of Common Stock, representing less than 2% of the total outstanding shares, which raises concerns about their alignment with public shareholders' risks [8][9].